


AMENDMENTS TO THE CLAIMS

Claims 1-22 (canceled).

Claim 23 (previously presented): A method of inactivating antigen-specific T cells in an individual in need of such treatment, comprising the step of administering to said individual an effective amount of a compound of structure



wherein n_1 is 1-5;

X is O or NH;

Y is O; and

R' is hydrogen, methyl or ethyl;

or a pharmaceutically acceptable salt thereof.

Claim 24 (original): The method of claim 23, wherein said compound is 2-(4-morpholinyl)ethyl butanamide or a pharmaceutically acceptable salt thereof.

Claim 25 (previously presented): The method of claim 23, wherein said compound is 2-(4-morpholinyl)ethyl butyrate or a pharmaceutically acceptable salt thereof.

Claim 26 (currently amended): The method of claim 23, wherein inactivation of antigen-specific T cells is useful in the prophylaxis or therapeutic treatment of an autoimmune disease[.] or a disorder involving an autoimmune component or a neoplastic disease.

Claim 27 (previously presented): The method of claim 26, wherein said autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, diabetes or multiple sclerosis.

Claim 28 (previously presented): The method of claim 26, wherein said disorder involving an autoimmune component is an allograft transplantation rejection or a xenograft transplantation rejection.

Claims 29-41 (cancelled)